1:5 Stock Split of Pharma Stock: Record Date To Be Declared; Pick For Smart Investors To Bet For 2025?

With top-notch facilities, IOL Chemicals and Pharmaceuticals Ltd. is a major participant in the specialty chemicals market and one of the top pharmaceutical (API) companies. In multiple significant therapeutic areas, including pain management, anti-convulsants, anti-diabetes, anti-cholesterol, and anti-platelets, IOLCP is widely used. APIs including Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, and Paracetamol are among the company's product offerings, along with speciality chemicals like Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid, Acetic Anhydride, and Acetyl Chloride. With a completely integrated production plant and an installed capacity of 12,000 TPA, the firm is the largest manufacturer of Ibuprofen in the world.

IOL Chemicals & Pharmaceuticals Stock Split

"We wish to inform you that the Board of Directors of the Company, at its meeting held on 27th December 2024, has approved, inter alia, the sub-division / split of each equity share of face value of Rs. 10/- (Rupees Ten only) each, fully paid-up into 5 (Five) equity shares of face value of Rs. 2/- (Rupee two only) each, fully paid-up, by alteration of Capital Clause of the Memorandum of Association of the Company. The proposed sub-division/split is subject to the approval of the Shareholders through Postal Ballot process. The Record Date for determining eligibility for the sub-division/split will be communicated in due course," said IOL Chemicals & Pharmaceuticals in a stock exchange filing.

"The split of equity shares will make the shares more affordable, thereby increasing its attractiveness to a wider range of investors. This move is expected to potentially boost investor participation and improve liquidity in the market," IOL Chemicals & Pharmaceuticals informed stock exchanges.

IOL Chemicals & Pharmaceuticals News

The Indian Chemical Council (ICC) recently granted IOL Chemicals and Pharmaceuticals Ltd the Responsible Care® label for a three-year term on December 25, 2024. The company has received authorisation to use the Responsible Care (RC) logo, making it the 100th company to do so.

"This achievement reflects our ongoing dedication to building a safe, ethical, and sustainable future, and we remain focused on driving progress in all areas of our business. Responsible Care is the commitment to ensure handling and managing the chemicals safely at every stage of their life cycle, while emphasizing their contribution to enhance the quality of life and supporting sustainable development," said IOL Chemicals & Pharmaceuticals in a regulatory filing.

IOL Chemicals & Pharmaceuticals Financials

On a stand-alone basis, the company's September 2024 quarter's net sales were Rs 525.75 crore, a 3.59% decrease from the September 2023 quarter's Rs 545.30 crore. In Q2FY25, its standalone net profit was Rs. 19.15 crore, a 49.33% drop from Q2FY24's Rs. 37.79 crore. EBITDA decreased 32.61% from Rs. 71.21 crore in the September 2023 quarter to Rs. 47.99 crore in the September 2024 quarter.

IOL Chemicals Share Price Target

"IOL Chemicals stock price is bearish on the Daily charts with strong resistance at 429. A Daily close below support of 405 could lead to a target of 368 in the near term," commented A R Ramachandran, Independent Research Analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.